The Company

Cerebriu was founded in 2018.

We are automating MRI for the future of diagnostic imaging, empowering radiologists, technologists and clinicians with optimized workflows, infusing clinical intelligence at the point of imaging

Diversity Enhances
Creativity

Nationalities

Knowledge is Key
to Progress

People With PhD or MD

Together We Can
Achieve More

Employees

Cerebriu’s Mission Is To Simplify Radiology By Infusing Clinical Intelligence at the Point of Imaging

Streamlining workflows and acquiring the right images for the right patient at the right time are our obssessions.

Cerebriu improves workflow efficiency and the quality of care in diagnostic imaging by automatically suggesting protocols adjustments during the MRI examination, identifying critical findings at the point of imaging and notifying the care team for fast radiological analysis and prompt patient management.

By using Cerebriu AI software, the care team can expect a reduction of interruptions to radiologists, an augmentation of technologists’ autonomy and confidence, a reduction of occupational stress, the optimization of MRI utilization with less unnecessary sequences, faster reporting of critical findings and a timely and efficient communication with the care team.

Since 2020 Cerebriu has been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labour, the environment and anti-corruption.

Leadership:

Robert Lauritzen

Chief Executive Officer

Robert is one of the co-founders and is an international IT life sciences executive with 25+ years of management experience across high-tech, MedTech, start-ups and large corporations across pharma and IT service providers, building and managing global delivery and sales execution across Europe, US and Asia.

Martin Lillholm, PhD

Chief Operating Officer

Prof. Lillholm is one of the co-founders and specialised in machine learning at the department of computer science at the University of Copenhagen. Martin holds an extensive background in compliance of medical devices, ensuring licenses to operate, regulatory compliance and quality certification. Previously Prof. Lillholm was the Deputy Head of the Department of Computer Science and worked in the industry. He holds a PhD from IT-University of Copenhagen in computer vision and a master’s from the University of Copenhagen.

Akshay Pai, PhD

Chief Technology Officer

Dr. Pai is one of the co-founders and has more than a decade of machine learning experience, focusing on medical imaging and key inventor across several patents and author or co-author of more than 50 research publications.

Kristine Wernerfelt

Chief Financial Officer

+15 years’ experience working with the strategic/CXO agenda across industries in a variety of settings across investment management, management consulting, corporate finance, solution selling.

CEREBRIU IN THE US:

Zac Durant

Vice President of BD

Zac has a strong commercial background managing strategic alliances, marketing strategy and brand development, with a focus on the US market. Previously at leading companies such as GE Healthcare, Zac developed business growth strategies within emerging segments for portfolio expansion. Zac holds a BS in Chemical Engineering and BA in Philosophy from University of Massachusetts Lowell.

OUR BOARD

Peter Savas

–

Chairman of the Board

About Peter

Mr. Savas brings over 30 years of experience in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Myers, Waters, Millipore, Genex and Zymark. With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.

Dr. Jonathan Gertler

Board member

About Jonathan

Jonathan P. Gertler joined BioVentures Investors in 2019 and is currently a Managing Director. He has over 35 years of scientific, clinical, entrepreneurial, transactional, and investment expertise in both academic medicine and in the life sciences sector. Dr. Gertler is also the co-founder, Managing Partner and CEO of Back Bay Life Science Advisors, a global life science consultancy and advisory group, and founder of three additional healthcare companies.

Homer Pien

PhD

Board Member

About Homer

Homer Pien currently serves on multiple boards, and was most recently SVP and Chief Scientific Officer at Philips for the Precision Diagnosis cluster of businesses, and prior to that Chief Technology Officer for Imaging System, at Philips as well. Before joining Philips in 2012, he was in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School, where he led the Laboratory for Medical Imaging and Computations. Homer was also at two start-ups, one of which was a biotech company he co-founded and served as CEO prior to the company being acquired. Earlier in his career Homer was at MIT Lincoln Lab and Draper Lab. Homer has a PhD in computer science from Northeastern University (Boston, MA), and MS Management from Massachusetts Institute of Technology (Cambridge, MA).

Ulrik Spork

–

Board Member

About

Ulrik Spork is active as Chairman, board member, and advisor in several emerging life-science and MedTech companies as well as two venture/PE funds-of-funds. For over 25 years Ulrik held senior positions in the Novo Group, where he effectively executed Novo Nordisk’s corporate development activities. He also founded and led as Senior/Managing Partner the Venture, Growth Equity, and Principal Investment activities in Novo Holdings A/S. He holds a master’s degree in engineering from Danish Technical University.

Claudia Colciago

PhD

Board member

About

Dr. Claudia Maria Colciago is a Senior Investment Manager in Denmark’s Export and Investment Fund and member of several boards. She previously held positions such as Associate Director at Takeda Digital Ventures. Prior to that, at MTIP she led a $20m+ financing round in Oviva and partook in the first and following investment in other portfolio companies such as Coramaze, Blueprint Genetics, Tyto Care, Lumeon, and Cynerio. She has a Ph.D. in Applied Mathematics from the École Polytechnique fédérale de Lausanne (EPFL), and a post-doc, where she led a proof-of-concept project of a digital health start-up.